Chris听currently听serves听on听several听corporate听boards,听including听Tragara听Pharmaceuticals,听Asterand听Corp.,Elcelyx听and听Nimbus听Pharmaceuticals,听and听achieved听successful听exits听with听Avidia,听Morphotech,听Threshold,听Scioderm听and Nimbus.听Previously, he served as the President and CEO of Ribozyme; Senior Vice President, Research at SmithKline Beecham; Vice President, Discovery Research at Upjohn and President, Colorado State University. He received the "Outstanding Research of Year" Award from the International Society of Quantum Biology, the "W. E. Upjohn Award" for contributions in biotechnology and a Lifetime Achievement Award and Lifetime Achievement Award听from the Colorado Biosciences Association. Chris currently serves on several corporate boards, including Catalyst Biosciences, Galleon Pharmaceuticals, GlobeImmune, Stemgent, Tragara Pharmaceuticals and OptiScan and achieved successful exits with Avidia, Morphotek, and Threshold. He earned a B.S. in Chemistry and Mathematics from Cornell University, a Ph.D. in Chemistry from Indiana University and an Honorary J.D. from Cornell College.